Beilstein J Org ChemBeilstein J Org ChemBeilstein Journal of Organic Chemistry1860-5397Beilstein-InstitutTrakehner Str. 7-9, 60487 Frankfurt am Main, Germany24611080394443010.3762/bjoc.10.43Full Research PaperChemistryOrganic ChemistryA catalyst-free multicomponent domino sequence for the diastereoselective synthesis of (E)-3-[2-arylcarbonyl-3-(arylamino)allyl]chromen-4-onesPrasannaPitchaimani1GunasekaranPethaiah1PerumalSubbusubbu.perum@gmail.com1MenéndezJ Carlosjosecm@farm.ucm.es2MüllerThomas J JGuest EditorDepartment of Organic Chemistry, School of Chemistry, Madurai Kamaraj University, Madurai - 625 021, Tamilnadu, IndiaDepartamento de Química Orgánica and Farmacéutica, Facultad de Farmacia, Universidad Complutense, 28040 Madrid, Spain201421220141045946510.3762/bjoc.10.43291020132112014Copyright © 2014, Prasanna et al; licensee Beilstein-Institut.2014Prasanna et al; licensee Beilstein-Institut.This is an Open Access article under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.The license is subject to the Beilstein Journal of Organic Chemistry terms and conditions: (http://www.beilstein-journals.org/bjoc)Summary

The three-component domino reactions of (E)-3-(dimethylamino)-1-arylprop-2-en-1-ones, 3-formylchromone and anilines under catalyst-free conditions afforded a library of novel (E)-3-(2-arylcarbonyl-3-(arylamino)allyl)-4H-chromen-4-ones in good to excellent yields and in a diastereoselective transformation. This transformation generates one C–C and one C–N bond and presumably proceeds via a reaction sequence comprising a Michael-type addition–elimination reaction, a nucleophilic attack of an enamine to a carbonyl reminiscent of one of the steps of the Bayllis–Hilman condensation, and a final deoxygenation. The deoxygenation is assumed to be induced by carbon monoxide resulting from the thermal decomposition of the dimethylformamide solvent.

chromonesdomino reactionsMichael additionsmulticomponent reactionstransfer hydrogenation

This article is part of the Thematic Series "Multicomponent reactions II".

Introduction

Chromones are widely present in nature, especially in the plant kingdom, and a wide variety of useful biological properties are associated with them [12]. Chromone derivatives act as effective tyrosine and protein kinase C inhibitors [3] and display antifungal [45], antimycobacterial [6], antiviral [7], antihypertensive [8], anti-oxidant [912], HIV-inhibitory [13], anti-inflammatory [1415], immunomodulatory [16], antithrombotic [17], and anticancer [1820] activities. Furthermore, some chromone derivatives have been identified as suitable fluorophores for live cell imaging [21]. In view of its importance chromone has emerged as a pharmacophore in drug discovery programmes, leading to several drugs in the market (e.g. cromolyn and nedocromil) and thereby continuing to draw the attention of synthetic organic and medicinal chemists [2224]. However, there are relatively few methods, which allow the preparation of hybrid structures containing chromone derivatives attached to other heterocyclic systems due to the lack of suitable building blocks. In order to come up with such building blocks, we planned the preparation of chromones containing a β-enaminone structural fragment, since enaminones are versatile starting materials in organic synthesis and are notably important for the synthesis of nitrogen heterocycles [2527]. In particular, β-enaminoketones are endowed with electrophilic and nucleophilic reaction centers and have a versatile reactivity that allows their application in the synthesis of important heterocycles such as indole [28], dihydropyridine [29], quinoline [30], pyrrole [31] and pyridinone [32]. Furthermore, they can take part in one-pot multicomponent reactions with both nucleophilic and electrophilic reactants, leading to a fast access to structurally diverse carbocycles and heterocycles, an area in which we have recently become interested [3342]. Thus, the present study ia a continuation of our research program on the construction of novel heterocycles employing one-pot green domino-multicomponent transformations [4354].

In order to achieve our goal, we embarked on the study of the three-component reactions between 3-formylchromone (1), (E)-3-(dimethylamino)-1-arylprop-2-en-1-ones 2 and anilines 3, which we expected to furnish novel (E)-3-[2-arylcarbonyl-3-(arylamino)allyl]-4H-chromen-4-ones 5 comprising the desired chromonone and β-enaminoketone moieties via intermediate species 4. The overall synthetic strategy is summarized in Scheme 1.

Summary of the transformations involved in the synthesis of compounds 5, containing chromone and β-enaminoketone moieties.

Results and Discussion

We started our study with the optimization of a model reaction between 3-formylchromone (1, 1 mmol), (E)-3-(dimethylamino)-1-(3-nitrophenyl)prop-2-en-1-one (1 mmol) and 4-methoxyaniline (1 mmol). This three-component reaction was initially examined in solvents such as acetonitrile, dioxane, dimethyl sulfoxide, toluene and ethanol under heating. However, the only isolable product was compound 4d, which originated from a reaction between the last two components without participation of the chromone substrate (Table 1, entries 1–5). The use of dimethylformamide as a solvent, on the other hand, allowed the isolation of the target (E)-3-[3-(4-methoxyphenylamino]-2-(3-nitrobenzoyl)allyl)-4H-chromen-4-one (5f). After temperature fine-tuning (Table 1, entries 6–11), we identified heating in DMF at 130 °C for 6 h as the optimal conditions, which afforded 5f in 94% yield (Table 1, entry 11).

Solvent screen and temperature optimization for the synthesis of compound 5f.


EntrySolventTime (h)Temp. (°C)Yield (%)a

1CH3CN1280b
2dioxane10102b
3DMSO10140b
4toluene10110b
5EtOH1078b
6DMF66027
7DMF68034
8DMF610043
9DMF611061
10DMF612074
11DMF613094

aIsolated yield after purification by column chromatography. bCompound 4d was obtained predominantly.

All the subsequent reactions of 3-formylchromone (1), (E)-3-(dimethylamino)-1-arylprop-2-en-1-ones 2 and substituted anilines 3 were performed under the optimal conditions (equimolecular amounts, DMF at 130 °C) and were completed in 6–7 h. After completion of the reaction, removal of the solvent and purification of the residue by column chromatography, (E)-3-[2-arylcarbonyl-3-(arylamino)allyl]-4H-chromen-4-ones 5 were obtained in pure form in 78–94% yields (Scheme 2 and Table 2). It is noteworthy, that a similar reaction, in which the less hindered, more reactive formaldehyde was employed as the aldehyde component, took a completely divergent course and afforded 5-arylcarbonyl-1,3-diarylhexahydropyrimidines arising from pseudo five-component reactions of (E)-3-(dimethylamino)-1-arylprop-2-en-1-ones, two molecules of formaldehyde and two molecules of aniline [55].

Synthesis of compounds 5.

Scope and yields of the synthesis of compounds 5.

EntryComp.ArAr'Time (h)Yield (%)a

1 5a C6H5 4-MeC6H4 685
2 5b 4-ClC6H4 4-MeC6H4 687
3 5c 3-NO2C6H4 4-MeC6H4 690
4 5d C6H5 4-MeOC6H4 689
5 5e 4-ClC6H4 4-MeOC6H4 691
6 5f 3-NO2C6H4 4-MeOC6H4 694
7 5g 4-ClC6H4 4-ClC6H4 686
8 5h 4-MeC6H4 4-ClC6H4 784
9 5i 4-MeOC6H4 4-ClC6H4 782
10 5j 3-NO2C6H4 4-ClC6H4 687
11 5k C6H5 4-BrC6H4 680
12 5l 4-MeC6H4 4-BrC6H4 681
13 5m 4-MeC6H4 4-FC6H4 783
14 5n 4-MeC6H4 3-NO2C6H4 778
15 5o 4-ClC6H4 C6H5 686
16 5p 3-NO2C6H4 C6H5 688

aIsolated yield after purification by column chromatography.

The structure of compounds 5 was deduced from one and two-dimensional NMR spectroscopic data, as detailed in Supporting Information File 1 for 5h as a representative example. The structure of 5h deduced from the NMR spectroscopic studies was subsequently confirmed by single-crystal X-ray crystallographic data, as shown in Fig. 1 [56].

X-ray structure of compound 5h.

Our initial mechanistic hypothesis accounting for the formation of compounds 5 is depicted in Scheme 3. An initial Michael addition–elimination reaction, leading to the exchange between the starting arylamine 3 and dimethylamine, explains the formation of intermediates 4, which were the final reaction products in most investigated solvents. However, in DMF, the enamine moiety of 4 attacks the aldehyde group in 1 giving rise to 6. This reaction resembles one of the steps of the Bayllis–Hilman condensation and is presumably promoted by the presence of traces of formic acid as a contaminant of the solvent [57].

Initial mechanistic proposal to explain the formation of compounds 5 that was ruled out by deuteration experiments.

We established the feasibility of the first step by showing that the reaction between two of our starting enaminones, namely 2a (Ar = Ph) and 2c (Ar = 3-NO2C6H4) with aniline under our standard reaction conditions (DMF, 130 °C) affords the corresponding compounds 4 after 3 h in 94% and 90% yields, respectively. As previously mentioned (Table 1), the nature of the solvent was found to be of critical importance, and the transformation of intermediate 4 into the final products 5 was found to work only in DMF, among many investigated solvents. Since the reaction between 4 and 1 is proposed to be catalyzed by acid, we carried out the multicomponent reaction in a selection of solvents (dioxane, acetonitrile, dimethyl sulfoxide, ethanol, ethylene glycol) in the presence of one equivalent of HCl, but all these attempts failed, while the same conditions were successful in DMF. These results can be explained by assuming that the initial aldol-type reaction between 1 and 4 to give 6 is reversible and is driven to completion by the reduction step, which takes place in DMF only. Thus, interestingly, the reaction does not stop at compound 6, but instead undergoes a reductive termination step, which leads to the final products 5. This reduction step is intriguing, and a first mechanistic possibility could be a hydride transfer from formate anion. While this mechanism might partly account for the observed reduction, we acknowledge that it is problematic to rely on solvent impurities to account for a stoichiometric reduction. Alternatively, dimethylformamide itself might have been the reducing agent. There are a few scattered literature reports on the use of DMF as a reducing agent, the first of which seems to be the reduction of diazonium tetrafluoroborate salts to arenes [58]. DMF has also been described as a reducing agent acting by hydride transfer in Pd-catalyzed processes, where the metal plays a critical role in the reduction by decomposing it and facilitating hydride transfer from a Pd intermediate [5961]. However, it is not clear whether the same type of reaction may take place under our conditions. In order to test this ideas experimentally, we carried out the reaction between 3-formylchromone (1), (E)-3-(dimethylamino)-1-(4-chlorophenyl)prop-2-en-1-one and p-toluidine in DMF-d 7. If the mechanistic hypothesis was correct, this reaction should lead to a d-7 intermediate and hence to a mixture of 5 and d-5, with the latter being major due to isotope effects in the tautomeric equilibrium. However, this reaction failed to show any incorporation of deuterium into 5, and therefore we had to abandon the hydride-transfer hypothesis.

We came up with an alternative explanation based on the well-known fact that DMF decomposes into dimethylamine and carbon monoxide at its boiling point. Carbon monoxide can act as a deoxygenating agent [62] and thus explain the transformation of 6 into 5 as shown in Scheme 4. Because of the synthetic interest of allylic and benzylic deoxygenations, further research into this reaction is under way in our laboratories.

Alternative mechanistic proposal based on a carbon monoxide-induced deoxygenation.

Conclusion

We have developed a facile three-component diastereoselective synthesis of novel (E)-3-[2-arylcarbonyl-3-(arylamino)allyl]-4H-chromen-4-ones containing chromone and β-enaminoketone structural fragments from simple, readily available starting materials in a one-pot operation and in good to excellent yields. This transformation occurs via a domino sequence of reactions, which generates one C–C and one C–N bond. Presumably, this transformation proceeds via a reaction sequence comprising a Michael-type addition–elimination reaction, a nucleophilic attack of an enamine to a carbonyl, and a final deoxygenation step. We propose that the deoxygenation step is induced by carbon monoxide resulting from thermal decomposition of the dimethylformamide solvent.

Experimental

General methods. Melting points were measured in open capillary tubes and are uncorrected. The 1H NMR, 13C NMR, DEPT, H,H-COSY, C,H-COSY and HMBC spectra were recorded on a Bruker (Avance) 300 MHz NMR instrument by using TMS as an internal standard and CDCl3 as a solvent. Standard Bruker software was used throughout. Chemical shifts are given in parts per million (δ-scale), and the coupling constants are given in Hertz. Silica gel-G plates (Merck) were used for TLC analysis with a mixture of petroleum ether (60–80 °C) and ethyl acetate as an eluent. Elemental analyses were performed on a Perkin Elmer 2400 Series II Elemental CHNS analyzer.

General procedure for the synthesis of ( E )-3-(2-arylcarbonyl-3-(arylamino)allyl)-4 H -chromen-4-one derivatives 5a–5p. In a similar manner as described in [55], a mixture of 3-formylchromone (1, 1 mmol), enaminone 2 (1 mmol) and aniline 3 (1 mmol) in DMF (5 mL) was heated at 130 °C for 6–7 h. The reaction progress was monitored by TLC. After completion of the reaction, the solvent was removed and the product was purified by column chromatography with a petroleum ether–ethyl acetate mixture (4:1 v/v) as an eluent to afford compounds 5. Characterization data for representative compounds are given below. The characterization data for the full library can be found in Supporting Information File 1.

(E)-3-(2-Benzoyl-3-(p-tolylamino)allyl)-4H-chromen-4-one (5a): Isolated yield 0.336 g (85%); colorless solid; mp 215–216 °C; 1H NMR (300 MHz, CDCl3, δ, ppm) 2.28 (s, 3H), 3.71 (s, 2H), 6.92 (d, J = 8.4 Hz, 2H), 7.08 (d, J = 8.1 Hz, 2H), 7.37–7.45 (m, 4H), 7.47–7.56 (m, 4H), 7.66–7.71 (m, 1H), 8.31 (d, J = 7.8 Hz, 1H), 8.52 (s, 1H), 9.93 (d, J = 12.6 Hz, 1H); 13C NMR (75 MHz, CDCl3, δ, ppm): 20.1, 20.6, 113.3, 115.8, 118.3, 123.7, 123.9, 125.0, 125.9, 128.0, 128.5, 129.8, 130.1, 132.3, 133.7, 138.9, 140.9, 146.6, 156.2, 156.7, 179.8, 195.0; HRMS–ESI (m/z): [M − H] calcd for C26H20NO3, 394.14432; found, 394.144817; Anal. calcd for C26H21NO3: C, 78.97; H, 5.35; N, 3.54; found: C, 79.02; H, 5.29; N, 3.62.

(E)-3-(2-(3-Nitrobenzoyl)-3-(p-tolylamino)allyl)-4H-chromen-4-one (5c): Isolated yield 0.396 g (90%); yellow solid; mp 206–207 °C; 1H NMR (300 MHz, CDCl3, δ, ppm) 2.32 (s, 3H), 3.72 (s, 2H), 6.93 (d, J = 8.4 Hz, 2H), 7.10 (d, J = 8.1 Hz, 2H), 7.40–753 (m, 3H), 7.59 (d, J = 8.0 Hz, 1H), 7.68–7.74 (m, 1H), 7.81 (d, J = 7.5 Hz, 1H), 8.28–8.35 (m, 3H), 8.51 (s, 1H), 10.2 (d, J = 12.6 Hz, 1H); 13C NMR (75 MHz, CDCl3, δ, ppm) 20.1, 20.7, 113.0, 116.2, 118.4, 123.3, 123.6, 123.7, 124.4, 125.2, 125.9, 129.2, 130.2, 133.1, 133.9, 134.1, 138.4, 142.5, 147.3, 148.0, 156.1, 156.7, 179.9, 191.8; HRMS–ESI (m/z): [M − H] calcd for C26H19N2O5, 439.12940; found, 439.12995; Anal. calcd for C26H20N2O5: C, 70.90; H, 4.58; N, 6.36; found: C, 70.84; H, 4.62; N, 6.29.

(E)-3-(3-(4-Chlorophenylamino)-2-(4-methylbenzoyl)allyl)-4H-chromen-4-one (5h): Isolated yield 0.361 g (84%); colorless solid; mp 219–220 °C; 1H NMR (300 MHz, CDCl3, δ, ppm) 2.40 (s, 3H), 3.70 (s, 2H), 6.95 (d, J = 8.7 Hz, 2H), 7.19–7.26 (m, 4H), 7.40–7.46 (m, 3H), 7.48–7.52 (m, 2H), 7.69 (t, J = 7.1 Hz, 1H), 8.30 (d, J = 7.2 Hz, 1H), 8.51 (s, 1H), 10.04 (d, J = 12.3 Hz, 1H); 13C NMR (75 MHz, CDCl3, δ, ppm) 20.4, 21.4, 114.4, 116.8, 118.4, 123.7, 125.1, 125.8, 127.4, 128.6, 128.8, 129.5, 133.8, 137.7, 140.1, 140.4, 145.3, 156.3, 156.7, 179.9, 195.2; HRMS–ESI (m/z): [M − H] calcd for C26H19ClNO3, 428.10535; found, 428.10589; Anal. calcd for C26H20ClNO3: C, 72.64; H, 4.69; N, 3.26; found: C, 72.57; H, 4.75; N, 3.31.

(E)-3-(3-(4-Bromophenylamino)-2-(4-methylbenzoyl)allyl)-4H-chromen-4-one (5l): Isolated yield 0.384 g (81%); colorless solid; mp 223–224 °C; 1H NMR (300 MHz, CDCl3, δ, ppm) 2.40 (s, 3H), 3.70 (s, 2H), 6.90 (d, J = 8.7 Hz, 2H), 7.21 (d, J = 8.1 Hz, 2H), 7.36–7.41 (m, 3H), 7.43–7.52 (m, 4H), 7.69 (dd, J = 7.5 Hz, 1.5 Hz, 1H), 8.30 (dd, J = 8.1 Hz, 1.8 Hz, 1H), 8.51 (s, 1H), 10.04 (d, J = 12.0 Hz, 1H); 13C NMR (75 MHz, CDCl3, δ, ppm) 20.4, 21.4, 114.5, 114.7, 117.2, 118.4, 123.6, 125.1, 125.8, 128.6, 128.8, 132.5, 133.8, 137.7, 140.4, 140.6, 145.1, 156.4, 156.7, 179.9, 195.2; HRMS–ESI (m/z): [M − H] calcd for C26H19BrNO3, 472.05483; found, 472.05538; Anal. calcd for C26H20BrNO3: C, 65.83; H, 4.25; N, 2.95; found: C, 65.70; H, 4.34; N, 2.91.

(E)-3-(2-(4-Chlorobenzoyl)-3-(phenylamino)allyl)-4H-chromen-4-one (5o): Isolated yield 0.357 g (86%); colorless solid; mp 245–246 °C; 1H NMR (300 MHz, CDCl3, δ, ppm) 3.71 (s, 2H), 7.00–7.05 (m, 3H), 7.26–7.33 (m, 2H), 7.37–7.40 (m, 2H), 7.44–7.55 (m, 5H), 7.67–7.72 (m, 1H), 8.31 (d, J = 7.8 Hz, 1H), 8.50 (s, 1H), 10.08 (d, J = 12.3 Hz, 1H); 13C NMR (75 MHz, CDCl3, δ, ppm) 20.2, 113.7, 115.9, 118.4, 122.9, 123.7, 125.1, 125.9, 128.4, 129.7, 129.9, 133.8, 136.1, 139.2, 141.1, 146.2, 156.2, 156.7, 179.8, 193.8; HRMS–ESI (m/z): [M − H] calcd for C25H17ClNO3, 414.08970; found, 414.09024; Anal. calcd for C25H18ClNO3: C, 72.20; H, 4.36; N, 3.37; found: C, 72.09; H, 4.24; N, 3.41.

General procedure for the isolation of intermediates 4. A mixture of the suitable enaminone 2 (1 mmol) and aniline 3 (1 mmol) in DMF (5 mL) was heated at 130 °C for 3 h. The reaction progress was monitored by TLC. After completion of the reaction, the solvent was removed and the product was purified by column chromatography with a petroleum ether–ethyl acetate mixture (4:1 v/v) as an eluent. Characterization data for compounds 4 can be found in Supporting Information File 1.

Supporting Information

Experimental details, full characterization data, detailed structural characterization of compound 5h and copies of the spectra of all compounds.

SP and JCM thank the Department of Science and Technology (India) and the Ministerio de Ciencia e Innovación (MICINN, Spain) for the Indo-Spanish collaborative research project, which has made this joint work possible (DST/INT/SPAIN/P-11/09 and ACI2009-0956, respectively). The authors acknowledge (i) the DST for granting a major research project to SP (No. SR/S1/OC-50/2011), (ii) the University Grants Commission for the award of a BSR Faculty Fellowship to SP, and (iii) the Ministerio de Economía y Competitividad (MINECO) for the grant CTQ-2012-33272-BQU to JCM. We also thank an anonymous reviewer for bringing reference [62] to our attention.

KumarRYusufMARKIVOC2006ix23926410.3998/ark.5550190.0007.908KhademSMarlesR JMolecules20121719120610.3390/molecules1701019122202807DyragerCNilsson MöllersLKjällL KAlaoJ PDinérPWallnerF KSunnerhagenPGrøtliMJ Med Chem2011547427743110.1021/jm200818j21905739MoriKAudranGMontiHSynlett199825926010.1055/s-1998-1628GhaniS B AMugishaP JWilcoxJ CGadoE A MMeduE OLambA JBrownR C DSynth Commun2013431549155610.1080/00397911.2011.647222China RajuBRaoR NSumanPYogeeswariPSriramDShaikT BKalivendiS VBioorg Med Chem Lett2011212855285910.1016/j.bmcl.2011.03.07921507635BhatA SWhetstoneJ LBrueggemeierR WTetrahedron Lett1999402469247210.1016/S0040-4039(99)00279-8WuE S CColeT EDavidsonT ABlosserJ CBorrelliA RKinsolvingC RMilgateT EParkerR BJ Med Chem19873078879210.1021/jm00388a0072883317PiettaP-GJ Nat Prod2000631035104210.1021/np990450910924197BennettC JCaldwellS TMcPhailD BMorriceP CDuthieG GHartleyR CBioorg Med Chem2004122079209810.1016/j.bmc.2004.02.03115080911KrishnamachariVLevineL HZhouCPareP WChem Res Toxicol20041779580410.1021/tx034242z15206900KumarMKumarSKaurSAfr J Pharm Pharmacol20115421427KhanI AAveryM ABurandtC LGoinsD KMikellJ RNashT EAzadeganAWalkerL AJ Nat Prod2000631414141610.1021/np000010d11076565KimH PSonK HChangH WKangS SJ Pharm Sci20049622924510.1254/jphs.CRJ04003XMiddletonEKandaswamiCTheoharidesT CPharmacol Rev20005267375111121513WangY-BHuangRZhangH-BLiLJ Asian Nat Prod Res2006866367010.1080/1028602050024630317135054LinC-NKuoS-HChungM-IKoF-NTengC-MJ Nat Prod19976085185310.1021/np970011e9287421BauvoisBPuiffeM-LBonguiJ-BPaillatSMonneretCDauzonneDJ Med Chem2003463900391310.1021/jm021109f12930151QuintinJRoullierCThoretSLewinGTetrahedron2006624038405110.1016/j.tet.2006.02.024MaicheenCJittikoonJVajraguptaOUngwitayatornJMed Chem2013932933910.2174/157340641130903000323030699DyragerCFribergADahlénKFridén-SaxinMBörjessonKWilhelmssonL MSmedhLGrøtliMLuthmanKChem–Eur J2009159417942310.1002/chem.20090027919670192EllisG PChromenes, Chromanones and Chromones1977New YorkJohn Wiley and SonsIbrahimM AAliT EAlnamerY AGabrY AARKIVOC2010i9813510.3998/ark.5550190.0011.103PintoD C G ASilvaA M SCurr Org Chem2012956157210.2174/157017912802651429LuePGreenhillJ VAdv Heterocycl Chem19966720734310.1016/S0065-2725(08)60072-0ElassarA-Z AEl-KhairA ATetrahedron2003598463848010.1016/S0040-4020(03)01201-8GovindhBDiwakarB SMurthyY L NOrg Commun20125105119BerniniRFabriziGSferrazzaACacchiSAngew Chem, Int Ed2009488078808110.1002/anie.200902440YangJWangCXieXLiHLiYEur J Org Chem20104189419310.1002/ejoc.201000607MahataP KVenkateshCSyam KumarU KIlaHJunjappaHJ Org Chem2003683966397510.1021/jo034053l12737579YanR-LLuoJWangC-XMaC-WHuangG-SLiangY-MJ Org Chem2010755395539710.1021/jo101022k20590089SchirokHAlonso-AlijaCBenet-BuchholzJGöllerA HGrosserRMichelsMPaulsenHJ Org Chem2005709463946910.1021/jo051542816268621TentiGEgeaJVillarroyaMLeónRFernándezJ CPadínJ FSridharanVRamosM TMenéndezJ CMed Chem Commun2013459059410.1039/c3md20345jRocchiDGonzálezJ FMenéndezJ CGreen Chem20131551151710.1039/c2gc36221jEstévezVVillacampaMMenéndezJ CChem Commun20134959159310.1039/c2cc38099dTentiGRamosM TMenéndezJ CACS Comb Sci20121455155710.1021/co300081k22954155MaitiSMenéndezJ CChem Commun201147105541055610.1039/c1cc11246eMaitiSSridharanVMenéndezJ CJ Comb Chem20101271372210.1021/cc100084b20593849SuryavanshiP ASridharanVMenéndezJ COrg Biomol Chem201083426343610.1039/c004703a20532396SridharanVMaitiSMenéndezJ CJ Org Chem2009749365937110.1021/jo902130919921805SridharanVMaitiSMenéndezJ CChem–Eur J2009154565457210.1002/chem.20090004419288482SridharanVMenéndezJ COrg Lett2008104303430610.1021/ol801738d18778079PrasannaPBalamuruganKPerumalSMenéndezJ CGreen Chem2011132123212910.1039/c0gc00952kRajeshS MBalaB DPerumalSMenéndezJ CGreen Chem2011133248325410.1039/c1gc15794aIndumathiSPerumalSMenéndezJ CTetrahedron2011677101710510.1016/j.tet.2011.06.107BalaB DBalamuruganKPerumalSTetrahedron Lett2011524562456610.1016/j.tetlet.2011.06.102BalamuruganKJeyachandranVPerumalSMenéndezJ CTetrahedron2011671432143710.1016/j.tet.2010.12.052KumarR SOsmanHPerumalSMenéndezJ CAliM AIsmailRChoonT STetrahedron2011673132313910.1016/j.tet.2011.02.058BalamuruganKPerumalSMenéndezJ CTetrahedron2011673201320810.1016/j.tet.2011.03.020IndumathiSPerumalSMenéndezJ CJ Org Chem20107547247510.1021/jo902132720014786BalamuruganKPerumalSReddyA S KYogeeswariPSriramDTetrahedron Lett2009506191619510.1016/j.tetlet.2009.08.085IndumathiSKumarR RPerumalSTetrahedron2007631411141610.1016/j.tet.2006.11.093SrinivasanMPerumalSTetrahedron2007632865287410.1016/j.tet.2007.01.038KarthikeyanS VPerumalSTetrahedron Lett2007482261226510.1016/j.tetlet.2007.01.168MuthusaravananSPerumalSAlmansourA ITetrahedron Lett2012531144114810.1016/j.tetlet.2011.12.097

Cambridge Crystallographic Database, CCDC number 894829.

PletnevA ATianQLarockR CJ Org Chem20026792769287And references cited therein.10.1021/jo026178g12492329MarxG SJ Org Chem1971361725172610.1021/jo00811a044ZawiszaA MMuzartJTetrahedron Lett2007486738674210.1016/j.tetlet.2007.07.077KimH SGowrisankarSKimS HKimJ NTetrahedron Lett2008493858386110.1016/j.tetlet.2008.04.080LiuBZhengGLiuXXuCLiuJWangMChem Commun2013492201220310.1039/c3cc37571dAiKLiuYLuLChengXHuoLJ Mater Chem2011213365337010.1039/c0jm02865g